Technology ID
TAB-3737
Structure-Based Design of A3 Adenosine Receptor-Selective 2-Arylethynyl (N)-methanocarba Nucleosides for Diagnostic and Therapeutic Uses
E-Numbers
E-075-2012-0
Lead Inventor
Jacobson, Kenneth (NIDDK)
Co-Inventors
Tosh, Dilip (NIDDK)
Applications
Therapeutics
Research Materials
Diagnostics
Therapeutic Areas
Ophthalmology
Oncology
Infectious Disease
Endocrinology
Dental
Cardiology
Lead IC
NIDDK
ICs
NIDDK
This technology includes compounds that are selective agonists of the A3 receptor for the treatment of various disorders such as cancer and autoinflammatory diseases. Structurally, these compounds extend the class of (N)-methanocarba derivatives that are selective agonists of the A3 receptor.
Commercial Applications
The discovery could be used in either a therapeutic or diagnostic mode. Other A3 agonists are in advanced clinical trials for treatment of various disorders such as hepatocellular carcinoma, autoimmune inflammatory diseases, and other conditions.
Competitive Advantages
This class of compounds produced full agonists of the human A3AR of nanomolar affinity that were consistently highly selective >1000-fold vs. A1AR and A2AAR.
Licensing Contact: